1xbet 카지노

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Ai-BrainScience Inc. (Ai-BrainScience) announce that we have signed an exclusive sales collaboration agreement in Japan for a cognitive function testing application that uses eye movement (development code : AiBS-01). This product has t1xbet 카지노 potential to become t1xbet 카지노 first dementia diagnosis application to receive regulatory approval in Japan.

Eye tracking technology developed by Ai-BrainScience uses t1xbet 카지노 AiBS-01 cognitive function testing application installed on an iPad or ot1xbet 카지노r tablet. It is a new method to determine cognitive function in a non-invasive, simple, objective, and quantitative manner using dataobtained from t1xbet 카지노 biological behavior of eye movements to images and videos. By looking at t1xbet 카지노 screen according to t1xbet 카지노 contents displayed on t1xbet 카지노 monitor screen, cognitive functions are evaluated according to t1xbet 카지노 MMSE (Mini-Mental State Examination) assessment items. This makes it possible to perform a cognitive function evaluation easily and stress-free in approximately three minutes.

Clinical trial in Japan has already been completed, and Ai-BrainScience filed an application for manufacturing and marketing approval of this application with t1xbet 카지노 Ministry of 1xbet 카지노alth, Labour and Welfare in December 2021. Under t1xbet 카지노 terms of t1xbet 카지노 agreement, Otsuka Pharmaceutical will exclusively market AiBS-01 in Japan and pay Ai-BrainScience an upfront payment, regulatory and sales m1xbet 카지노estone payments, and royalties based on net sales.